Essential1 Study

Research Studies

Praxis Precision Medicines is excited to announce the Essential1 study in essential tremor has completed screening for patients and we expect to be able to share topline results in quarter one of 2023.  On the heels of the positive topline results from our Phase 2a study we are encouraged by the profile of PRAX-944 and look forward to sharing these data in the coming months. We would like to thank everyone involved in helping us complete our enrollment in this clinical study, including the patients, caregivers and advocacy collaborators, including IETF. Please click below to sign up for communications from Praxis on essential tremor and trial updates.

Sign up here